KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBITDA Margin: 2010-2024

Historic EBITDA Margin for TherapeuticsMD (TXMD) over the last 15 years, with Dec 2024 value amounting to -270.30%.

  • TherapeuticsMD's EBITDA Margin rose 9736.00% to -109.95% in Q3 2025 from the same period last year, while for Sep 2025 it was -61.80%, marking a year-over-year increase of 31088.00%. This contributed to the annual value of -270.30% for FY2024, which is 51910.00% up from last year.
  • Per TherapeuticsMD's latest filing, its EBITDA Margin stood at -270.30% for FY2024, which was up 65.76% from -789.40% recorded in FY2023.
  • TherapeuticsMD's 5-year EBITDA Margin high stood at 160.08% for FY2022, and its period low was -6,700.93% during FY2021.
  • Over the past 3 years, TherapeuticsMD's median EBITDA Margin value was -270.30% (recorded in 2024), while the average stood at -299.87%.
  • In the last 5 years, TherapeuticsMD's EBITDA Margin crashed by 641,803bps in 2021 and then skyrocketed by 686,101bps in 2022.
  • Yearly analysis of 5 years shows TherapeuticsMD's EBITDA Margin stood at -282.90% in 2020, then crashed by 641,803bps to -6,700.93% in 2021, then spiked by 686,101bps to 160.08% in 2022, then plummeted by 94,948bps to -789.40% in 2023, then surged by 51,910bps to -270.30% in 2024.